Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial

Fig. 3

Responder analyses for patients with improvement equal to or greater than the minimal clinically important difference (MCID). a Differences from placebo in the percentage of patients reporting improvement equal to or greater than the MCID after 24 weeks of treatment according to patient global assessment (PtGA), pain, functional assessment of chronic illness therapy-fatigue (FACIT-F), health assessment questionnaire-disability index (HAQ-DI), and the Short Form 36 (SF-36) physical and mental component scores. b Differences from placebo in the percentage of patients reporting improvements equal to or greater than the MCID after 24 weeks of treatment in SF-36 domain scores. PF physical functioning, RP role physical, BP body pain, GH general health, VT vitality, SF social functioning, RE role emotional, MH mental health, NNT number needed to treat for sarilumab + methotrexate (MTX) versus placebo + MTX

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us